Sponsored by
This trial was discussed during our May Brain Tumor Awareness Month Webinar series: see here. The treatment used to be called PVSRIPO, but it's now called Lerapolturev. The trial is now recruiting, with the aim of enrolling up to 80 patients with supratentorial recurrent glioblastoma who are eligible for maximal safe resection for their recurrence.